PT  - JOURNAL ARTICLE
AU  - Iqbal, Khizer
AU  - Sinha, Saptarshi
AU  - David, Paula
AU  - De Marco, Gabriele
AU  - Taheri, Sahar
AU  - McLaren, Ella
AU  - Maisuria, Sheetal
AU  - Arumugakani, Gururaj
AU  - Ash, Zoe
AU  - Buckley, Catrin
AU  - Coles, Lauren
AU  - Hettiarachchi, Chamila
AU  - Smithson, Gayle
AU  - Slade, Maria
AU  - Shah, Rahul
AU  - Marzo-Ortega, Helena
AU  - Keen, Mansoor
AU  - Lawson, Catherine
AU  - Mclorinan, Joanna
AU  - Nizam, Sharmin
AU  - Reddy, Hanu
AU  - Sharif, Omer
AU  - Sultan, Shabina
AU  - Tran, Gui
AU  - Wood, Mark
AU  - Wood, Samuel
AU  - Ghosh, Pradipta
AU  - McGonagle, Dennis
TI  - MDA5-autoimmunity and Interstitial Pneumonitis Contemporaneous with the COVID-19 Pandemic (MIP-C)
AID  - 10.1101/2023.11.03.23297727
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.03.23297727
4099  - http://medrxiv.org/content/early/2023/11/05/2023.11.03.23297727.short
4100  - http://medrxiv.org/content/early/2023/11/05/2023.11.03.23297727.full
AB  - Background Anti-MDA5 (Melanoma differentiation-associated protein-5) positive dermatomyositis (MDA5+-DM) is characterised by rapidly progressive interstitial lung disease (ILD) and high mortality. MDA5 senses single-stranded RNA and is a key pattern recognition receptor for the SARS-CoV-2 virus.Methods This is a retrospective observational study of a surge in MDA5 autoimmunity, as determined using a 15 muscle-specific autoantibodies (MSAs) panel, between Janurary 2018-December 2022 in Yorkshire, UK. MDA5-positivity was correlated with clinical features and outcome, and regional SARS-CoV-2 positivity and vaccination rates. Gene expression patterns in COVID-19 were compared with autoimmune lung disease and idiopathic pulmonary fibrosis (IPF) to gain clues into the genesis of the observed MDA5+-DM outbreak.Results Sixty new anti-MDA5+, but not other MSAs surged between 2020-2022, increasing from 0.4% in 2019 to 2.1% (2020), 4.8% (2021) and 1.7% (2022). Few (8/60) had a prior history of confirmed COVID-19, peak rates overlapped with regional SARS-COV-2 community positivity rates in 2021, and 58% (35/60) had received anti-SARS-CoV-2 RNA vaccines. Few (8/60) had a prior history of COVID-19, whereas 58% (35/60) had received anti-SARS-CoV-2 RNA vaccines. 25/60 cases developed ILD which rapidly progression with death in 8 cases. Among the 35/60 non-ILD cases, 14 had myositis, 17 Raynaud phenomena and 10 had dermatomyositis spectrum rashes. Transcriptomic studies showed strong IFIH1 (gene encoding for MDA5) induction in COVID-19 and autoimmune-ILD, but not IPF, and IFIH1 strongly correlated with an IL-15-centric type-1 interferon response and an activated CD8+ T cell signature that is an immunologic hallmark of progressive ILD in the setting of systemic autoimmune rheumatic diseases. The IFIH1 rs1990760TT variant blunted such response.Conclusions A distinct pattern of MDA5-autoimmunity cases surged contemporaneously with circulation of the SARS-COV-2 virus during COVID-19. Bioinformatic insights suggest a shared immunopathology with known autoimmune lung disease mechanisms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), and in part by the National Institutes for Health (NIH) grant R01-AI155696 and pilot awards from the UC Office of the President (UCOP)-RGPO (R00RG2628, R00RG2642 and R01RG3780) to P.G. S.S was supported in part by R01-AI141630 (to P.G) and in part through funds from the American Association of Immunologists (AAI) Intersect Fellowship Program for Computational Scientists and Immunologists.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of University of Leeds, UK waived ethical approval for this work. This study was reported according to the CAse REports (CARE) guidelines [https://www.care-statement.org/]. All participants recruited granted verbal or written consent to the local treating physicians for the use of their anonymized data. An approved retrospective audit of service delivery at our institution, and a formal Institutional Research Board approval was not needed.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes